CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 220 enrolled
Drug / intervention
Palbociclib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03147287
NCT03147287Phase 2Active
CompareCT.gov

Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer

Dana-Farber Cancer Institute·interventional·Posted May 10, 2017·Updated Sep 30, 2025

In Brief

A Phase 2 clinical trial evaluating Palbociclib, Fulvestrant, and 1 other intervention for Metastatic Breast Cancer. Active but no longer recruiting, targeting 220 participants across 22 sites.

Detailed Summary

This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: -Fulvestrant -Fulvestrant with Palbociclib -Fulvestrant with Palbociclib and Avelumab

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2ActiveOverdue
201820192020202120222023202420252026
First PostedMay 10, 2017
Enrollment StartSep 5, 2017
Primary CompletionDec 31, 2022
Study CompletionJun 30, 2026
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 9.1 years ago

Interventions

Palbociclibdrug

Palbociclib is a drug that may stop cancer cells from growing

Fulvestrantdrug

Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen

Avelumabdrug

Avelumab is an antibody designed to block the PD-1 pathway and helps the immune system in detecting and fighting cancer cells